1. Home
  2. FHTX vs KELYB Comparison

FHTX vs KELYB Comparison

Compare FHTX & KELYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FHTX
  • KELYB
  • Stock Information
  • Founded
  • FHTX 2015
  • KELYB 1946
  • Country
  • FHTX United States
  • KELYB United States
  • Employees
  • FHTX N/A
  • KELYB N/A
  • Industry
  • FHTX Medicinal Chemicals and Botanical Products
  • KELYB Professional Services
  • Sector
  • FHTX Health Care
  • KELYB Consumer Discretionary
  • Exchange
  • FHTX Nasdaq
  • KELYB Nasdaq
  • Market Cap
  • FHTX 513.7M
  • KELYB 519.5M
  • IPO Year
  • FHTX 2020
  • KELYB N/A
  • Fundamental
  • Price
  • FHTX $5.14
  • KELYB $14.00
  • Analyst Decision
  • FHTX Strong Buy
  • KELYB
  • Analyst Count
  • FHTX 5
  • KELYB 0
  • Target Price
  • FHTX $13.80
  • KELYB N/A
  • AVG Volume (30 Days)
  • FHTX 197.3K
  • KELYB 381.0
  • Earning Date
  • FHTX 11-04-2024
  • KELYB 02-13-2025
  • Dividend Yield
  • FHTX N/A
  • KELYB 2.14%
  • EPS Growth
  • FHTX N/A
  • KELYB 80.11
  • EPS
  • FHTX N/A
  • KELYB 1.16
  • Revenue
  • FHTX $25,515,000.00
  • KELYB $4,372,900,000.00
  • Revenue This Year
  • FHTX N/A
  • KELYB N/A
  • Revenue Next Year
  • FHTX $11.54
  • KELYB $8.21
  • P/E Ratio
  • FHTX N/A
  • KELYB $11.22
  • Revenue Growth
  • FHTX N/A
  • KELYB N/A
  • 52 Week Low
  • FHTX $2.70
  • KELYB $14.00
  • 52 Week High
  • FHTX $10.25
  • KELYB $25.00
  • Technical
  • Relative Strength Index (RSI)
  • FHTX 27.35
  • KELYB 21.28
  • Support Level
  • FHTX $4.69
  • KELYB $14.20
  • Resistance Level
  • FHTX $5.70
  • KELYB $15.50
  • Average True Range (ATR)
  • FHTX 0.61
  • KELYB 0.01
  • MACD
  • FHTX -0.14
  • KELYB 0.09
  • Stochastic Oscillator
  • FHTX 16.24
  • KELYB 0.00

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

About KELYB Kelly Services Inc. Class B

Kelly Services Inc is a provider of workforce solutions and consulting and staffing services. The company's operations are divided into five business segments namely Professional & Industrial, Science, Engineering & Technology, Education, Outsourcing & Consulting, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.

Share on Social Networks: